The bcl-3 gene at chromosome 19q13 encodes a member of the IjB family involved in regulating the NFjB pathway. Originally identified by its involvement in the rare t(14:19)(q32;q13), BCL-3 expression has never been analyzed in a wide variety of lymphomas. We assessed BCL-3 expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma using formalin-fixed, paraffin-embedded tissue specimens, a monoclonal antibody specific for BCL-3, and immunohistochemical methods. Of 172 B-cell lymphomas, 10 (6%) were positive for BCL-3, including six of 23 (26%) diffuse large B-cell lymphoma, one of 17 (6%) small lymphocytic lymphoma, one of 26 (4%) follicular lymphoma, and two of 49 (4%) mantle cell lymphoma. All other B-cell neoplasms were negative, including marginal zone lymphoma (n ¼ 24, 11 extranodal, nine nodal, four splenic), Burkitt lymphoma (n ¼ 10), lymphoplasmacytic lymphoma (n ¼ 10), lymphoblastic lymphoma (n ¼ 8), and plasmacytoma (n ¼ 5). Of 111 T/NK-cell lymphomas, 25 (23%) were positive for BCL-3, including 13 of 40 (32%) anaplastic large-cell lymphoma, three of 10 (30%) angioimmunoblastic T-cell lymphoma, two of eight (25%) extranodal NK/T-cell lymphoma of nasal type, three of 12 (25%) mycosis fungoides, one of five (20%) enteropathy-type T-cell lymphoma, and two of 21 (10%) peripheral T-cell lymphoma unspecified. All other T-cell neoplasms were negative, including lymphoblastic lymphoma (n ¼ 6), prolymphocytic leukemia (n ¼ 6), and subcutaneous panniculitis-like T-cell lymphoma (n ¼ 3). Of 70 Hodgkin lymphomas, of all types, 29 (41%) were positive for BCL-3. The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies.
The bcl-3 gene, located at chromosome 19q13, was originally identified by its involvement in the t(14:19)(q32;q13). In this translocation, bcl-3 is juxtaposed with the immunoglobulin heavy chain gene locus at 14q32. 1 The t(14;19) was first described in 1983 1 and 2 years later was reported to be associated with chronic lymphocytic leukemia/small lymphocytic lymphoma with atypical morphology. 2 McKeithan et al 3 first cloned the bcl-3 gene in 1987.
BCL-3 encodes an IkB-like protein that regulates NFkB/Rel transcription factors. 4 The mammalian NFkB/Rel family consists of five known members: p50/p105, p52/p100, RelA (p65), c-Rel, and RelB. 4 These proteins are normally found in the cell cytoplasm, complexed with inhibitory IkB molecules, but when IkB proteins are degraded free NFkB/Rel family proteins can translocate to the nucleus and activate expression of a variety of genes. The IkB family, in addition to BCL-3, is composed of four other members, IkBa, IkBb, IkBe, and IkBg. BCL-3 is unique among the members of this family because it is located predominantly in the nucleus, it interacts with p50 and p52 homodimers of NFkB and it binds to other nuclear proteins (e.g. JAB-1) that can bind to transcription factors (e.g. C-JUN). 5 These data suggest that BCL-3 is an adaptor protein between NK-kB p50/p52 and other transcriptional regulators. 5 The t (14;19) or bcl-3 gene rearrangement has been reported rarely in non-Hodgkin lymphomas, in approximately 35 cases, mostly in cases of chronic lymphocytic leukemia/small lymphocytic lymphoma, and less frequently in cases designated as follicular lymphoma, diffuse large B-cell lymphoma, Burkitt-like lymphoma, and one case of acute biphenotypic leukemia. [6] [7] [8] [9] [10] [11] [12] Although the t(14;19) is rare, BCL-3 expression has been shown in a few types of non-Hodgkin lymphoma not known to carry the t (14;19) . For example, two recent studies have shown high levels of BCL-3 expression in ALKpositive anaplastic large-cell lymphoma. 13, 14 However, presence or absence of BCL-3 expression is unknown for most of the wide variety of lymphoma types defined in the recently published World Health Organization (WHO) classification. 15 In this study, we used an immunohistochemical method and a commercially available monoclonal antibody specific for BCL-3 to assess for expression in 353 cases of non-Hodgkin lymphoma and Hodgkin lymphoma.
Materials and methods

Study Group
A total of 353 lymphomas were collected from the files of the Department of Hematopathology of The University of Texas MD Anderson Cancer Center between 1998 and 2003. The diagnosis of all tumors was based on morphologic and immunohistochemical criteria according to the WHO classification. 15 The group of B-cell lymphomas included 49 mantle cell lymphoma, 26 follicular lymphoma (seven grade I, nine grade II and 10 grade III), 23 diffuse large B-cell lymphoma, 17 small lymphocytic lymphoma/chronic lymphocytic leukemia, 11 extranodal marginal zone B-cell lymphoma, 10 Burkitt lymphoma, 10 lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia, nine nodal marginal zone B-cell lymphoma, eight precursor B-lymphoblastic lymphoma/leukemia, five plasmacytoma, and four splenic marginal zone lymphoma. The group of T-cell lymphomas included 40 anaplastic large-cell lymphoma, 21 peripheral T-cell lymphoma, unspecified, 12 mycosis fungoides, 10 angioimmunoblastic T-cell lymphoma, eight extranodal NK/T-cell lymphoma of nasal-type, six T-cell prolymphocytic leukemia, six precursor T-lymphoblastic lymphoma/leukemia, five enteropathy-type T-cell lymphoma, and three subcutaneous panniculitis-like T-cell lymphoma. The group of Hodgkin lymphoma cases included 43 nodular sclerosis, 13 nodular lymphocyte predominant, 11 mixed cellularity, and three lymphocyte-rich classical. Five cases of reactive follicular hyperplasia were also studied.
Tumors were analyzed using either full tissue sections (n ¼ 217) or tissue microarrays (n ¼ 136). The tissue microarrays included triplicate or quadruplet tumor cores from all 136 tumors and were constructed using a manual tissue arrayer (Beecher Instruments, Silver Springs, MD, USA) as described previously. 16, 17 All cases were fixed in 10% buffered formalin, routinely processed, and embedded in paraffin.
Immunohistochemical Methods
Tissue sections (3 or 4 mm thick) were deparaffinized in xylene and rehydrated in a graded series of ethanols. Heat-induced epitope retrieval was performed. Tissue sections were placed in plastic Coplin jars containing preheated target retrieval solution (DAKO) heated in a household vegetable steamer (Sunbeam-Oster, Model Sunbeam 4713/ 5710, 900 W) for 35 min, and allowed to cool at room temperature for at least 15 min. We used a monoclonal antibody specific for BCL-3 (clone 1E8, Novacastra, Newcastle upon Tyne, UK) at a dilution of 1:50. Subsequent steps of the immunostaining procedure were performed in a humidity chamber as previously described. 18 These steps included: (1) blocking of endogenous peroxidase in 3% H 2 O 2 in phosphate buffered saline (PBS), pH 7.4, for 5 min; (2) blocking of nonspecific protein-binding sites using protein blocking solution (DAKO) for 5 min; (3) incubation with the primary antibody overnight; and (4) detection using the streptavidinbiotin-peroxidase based LSAB þ kit (DAKO) for 2 Â 15 min. We used 3,3 0 diaminobenzidine/H 2 O 2 (DAKO) as the chromogen and hematoxylin as the counterstain.
Scoring of Positive Cells
Only nuclear staining was considered positive for BCL-3, irrespective of intensity, as the protein has been shown to be located predominantly within the nucleus. 5 At least 500 tumor cells were counted in each case. Positivity was defined as equal to or greater than 20% positive cells. However, almost all negative tumors were completely negative or tumors had o5% positive cells and positive tumors showed a range of positive cells, always over 20% and, in some cases, over 50%.
Results
Benign Lymphoid Tissues
Reactivity for BCL-3 in five reactive tissue specimens was confined to endothelial cells and follicular dendritic cells within germinal centers. Lymphoid cells were negative for BCL-3. Table 1 summarizes the BCL-3 results in various types of B-cell non-Hodgkin lymphoma. Of 172 B-cell lymphomas, 10 (6%) were BCL-3 positive, including six of 23 (26%) diffuse large B-cell lymphoma, one of 17 (6%) small lymphocytic lymphoma/chronic lymphocytic leukemia, one of 26 (4%) follicular lymphoma, and two of 49 (4%) mantle cell lymphoma ( Figure 1 ). The positive case of follicular lymphoma was grade III and both
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O Canoz et al positive cases of mantle cell lymphoma had pleomorphic blastoid morphology. All other B-cell neoplasms were negative, including extranodal marginal zone B-cell lymphoma (n ¼ 11), Burkitt lymphoma (n ¼ 10), lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia (n ¼ 10), nodal marginal zone B-cell lymphoma (n ¼ 9), precursor B-cell lymphoblastic lymphoma/leukemia (n ¼ 8), plasmacytoma (n ¼ 5), and splenic marginal zone lymphoma (n ¼ 4). Table 2 summarizes the BCL-3 results in various types of T-cell lymphoma. Of 111 T-cell lymphomas, 25 (23%) were BCL-3 positive, including 13 of 40 (32%) anaplastic large-cell lymphoma, three of 10 (30%) angioimmunoblastic T-cell lymphoma, three of 12 (25%) mycosis fungoides, two of eight (25%) extranodal NK/T-cell lymphoma of nasal-type, one of five enteropathy-type T-cell lymphoma (20%), and two of 21 (10%) peripheral T-cell lymphoma unspecified ( Figure 2 ). All other T-cell neoplasms were negative including precursor T-cell lymphoblastic lymphoma/leukemia (n ¼ 6), T-cell prolymphocytic leukemia (n ¼ 6), and subcutaneous panniculitis-like T-cell lymphoma (n ¼ 3). In anaplastic large-cell lymphomas, BCL-3 expression correlated with ALK-positivity (10/14 ALK þ vs 3/26 ALK-; P ¼ 0.015, Fisher's exact test). All three angioimmunoblastic T-cell lymphomas positive for BCL-3 were relatively high grade with many aggregates of large cells. One of the three positive cases of mycosis fungoides had transformed to large-cell lymphoma (425% large cells); the other two were consistent with patch (n ¼ 1) and plaque (n ¼ 1) stage. Table 3 
Discussion
As most prior studies of the bcl-3 gene have been performed using molecular genetic methods, and BCL-3 expression has been analyzed infrequently, the aim of this study was to assess for BCL-3 expression in reactive tissues and a wide variety of non-Hodgkin and Hodgkin lymphomas as defined using WHO classification criteria. 15 We show that a subset of neoplasms in a number of lymphoma types express BCL-3. These neoplasms included Hodgkin lymphoma (41%), anaplastic large-cell lymphoma (32%), angioimmunoblastic T-cell lymphoma (30%), diffuse large B-cell lymphoma (26%), extranodal NK/T-cell lymphoma of nasal-type (25%), mycosis fungoides (25%), enteropathy-type T-cell lymphoma (20%), peripheral T-cell lymphoma unspecified (10%), and rare cases of small lymphocytic lymphoma/chronic lymphocytic leukemia (6%), follicular lymphoma (4%), and mantle cell lymphoma (4%).
The bcl-3 gene was originally identified by its involvement in the t(14;19). BCL-3 is a member of the IkB family that includes at least four other members: IkBa, IkBb, IkBg, and IkBe. Treatment of 
BCL-3 in lymphomas O Canoz et al cells with various inducers results in degradation of
IkB proteins. Although NF-kB normally exists in inactive form in the cytoplasm of most cells, when IkB is degraded, bound NF-kB is released and translocated to the nucleus where it activates target genes. 4, 5 Although some of the IkB proteins are known to be inhibitors of transcription, it has been shown that BCL-3 interacts with general transcription factors, transcriptional coactivators and also other DNA-binding factors, all of which support a general role for BCL-3 in transcriptional activation. 4, 5 BCL-3 is thought to have many roles. bcl-3 gene expression is induced by many cell growth-or survival-promoting factors in lymphoid cell lines, suggesting that BCL-3 is involved in cell proliferation and survival. 19 In one study, transgenic mice expressing BCL-3 were found to have an expansion of B-cells in vivo, 20 further suggesting a role for BCL-3 in cell proliferation or survival. On the other hand, BCL-3-deficient mice are susceptible to certain Table 2 
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O Canoz et al kinds of pathogens, and antigen-specific antibody production was markedly inhibited. Others have hypothesized that bcl-3 directly regulates class switch recombination and somatic hypermutation, because these genetic alterations closely correlate with transcriptional activation of the immunoglobulin genes. 21 BCL-3 also can bind to the promoter of cyclin D1, enhancing progression of the cell cycle from G1 to S phase. 4, 22 Several studies have shown that BCL-3 is activated and may play a role in human breast cancer, 23 mouse skin carcinogenesis, 24 and hepatocyte proliferation, 25 which suggest that BCL-3 is involved in carcinogenesis and cell growth. Additionally, it was reported that BCL-3 affects retinoid X receptor functions in some tissues, and that retinoid X receptor plays a role in the potential tumorigenesis mediated by BCL-3. 26 In this study, diffuse large B-cell lymphoma was the type of B-cell lymphoma most commonly positive for BCL-3, in approximately one-quarter of cases. Au et al 12 previously reported four B-cell lymphomas that carried the t(14;19), including two small lymphocytic lymphoma/chronic lymphocytic leukemia, one diffuse large B-cell lymphoma, and one Burkitt-like lymphoma. They suggested that the cases of diffuse large B-cell and Burkitt-like lymphoma evolved from a prior low-grade small lymphocytic lymphoma/chronic lymphocytic leukemia. In this study, all six diffuse large B-cell lymphomas occurred de novo. Furthermore, in a transgenic mice model, the bcl-3 transgene increased the accumulation of both CD5-positive and CD5-negative B-lymphocytes. 20 This finding suggests that BCL-3 is involved in the pathogenesis of de novo DLBL, rather than in small lymphocytic lymphoma/chronic lymphocytic leukemia with progression to higher-grade B-cell lymphoma.
In small lymphocytic lymphoma/chronic lymphocytic leukemia, the prevalence of the t(14;19) is low, o1% by cytogenetic analysis and ranging from 0 to 2% by molecular genetic analysis. 2, 7, 12, [27] [28] [29] In these reported cases, aberrant immunophenotype (CD11c expression), atypical morphology, young patient age, and progressive disease were common. 2, 12, 28 In this study, BCL-3 positivity was found in one of 17 small lymphocytic lymphoma/chronic lymphocytic leukemia cases assessed. In the BCL-3 positive case, the patient was 65 years old and the morphology was typical. Cytogenetic analysis was not performed on this case.
We detected BCL-3 expression in a subset of cases of many types of T-cell lymphoma. There is precedent for this observation in the literature. BCL-3 expression in interleukin 4-deprived T cells protects these cells from apoptosis. 19 In anaplastic large-cell lymphoma, a prior study has shown that BCL-3 expression and both genetic and epigenetic modifications of the bcl-3 gene may be associated with oncogenesis. 13 Izban and colleagues 30 have reported that NF-kB p65 is expressed in cutaneous T-cell lymphoma cell lines and neoplastic T lymphocytes from patient samples of mycosis fungoides, and they also showed that nuclear NF-kB activity is required for cell survival and resistance to apoptosis in the neoplastic cells. Although BCL-3 has a strong preference towards p50 and p52 It is also known that stimuli such as tumor necrosis factor a, interleukin1b not only cause nuclear accumulation of p50-p65 heterodimers, but also induce formation of BCL-3-p50 complexes. 31 The data for B-and T-cell non-Hodgkin lymphomas suggest that BCL-3 expression correlates with cytologic grade (large cell morphology). In B-cell lymphomas, in addition to diffuse large B-cell lymphoma (26%), three of the other four positive lymphomas included one grade III follicular lymphoma and two blastoid mantle cell lymphomas. In T-cell lymphomas, BCL-3 was positive in one-third of anaplastic large-cell lymphoma, 30% of angioimmunoblastic T-cell lymphoma, and approximately a quarter of extranodal NK/T-cell lymphoma of nasaltype and enteropathy-type T-cell lymphoma. In the latter three categories of T-cell lymphoma, all positive neoplasms were composed predominantly of large cells. However, only one of the three BCL-3-positive cases of mycosis fungoides was transformed to large-cell lymphoma. In anaplastic largecell lymphomas, BCL-3 positivity also correlated with ALK expression (71% ALK þ vs 12% ALKÀ; P ¼ 0.015).
Hodgkin lymphoma was the first hematopoietic tumor in which aberrant constitutive NF-kB activation was described. In most Hodgkin lymphoma cases, IkBa is mutated and expression of RelA/p65 subunit is required for growth of Hodgkin lymphoma. 32 In our study, approximately 40% of Hodgkin lymphoma cases were BCL-3 positive. It has been proposed that BCL-3 is an activator of transcription, either by removing p50 homodimers from kB sites and allowing p65/p50 transactivating complexes to target DNA, 33 or by coactivation through p50 homodimers. Hinz et al 34 reported that cell death protection is a key function of constitutive NF-kB activity in Reed-Sternberg and Hodgkin cells, but the underlying pathogenesis is more complex. Hinz et al, used large-scale gene profiling to show that NF-kB regulates a complex network of genes, including signal transducer and activator of transcription (STAT) 5a, interleukin 13, and CC chemokine receptor 7 that are expressed in primary and cultured Reed-Sternberg and Hodgkin cells. 34 Although almost all BCL-3-positive cases of lymphoma exhibited only a nuclear pattern of positivity, a few cases also showed weaker cytoplasmic positivity in B-cell lymphomas. In addition, rare cases of B-cell lymphoma only had weak cytoplasmic positivity (two diffuse large B-cell lymphoma, two lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia and one small lymphocytic lymphoma/chronic lymphocytic leukemia). Whether this staining is true immunoreactivity or background staining is difficult to determine with certainty, but this phenomenon seemed to occur more often in tumors with plasmacytoid differentiation. As the location of BCL-3 protein has been shown to be predominantly nuclear within the cell, we did not consider these rare B-cell lymphomas with only cytoplasmic staining to be truly positive.
In conclusion, we performed an immunohistochemical study for BCL-3 in the 353 cases of nonHodgkin and Hodgkin lymphoma. Our results indicate that a subset of T-cell lymphomas, diffuse large B-cell lymphomas, and Hodgkin lymphomas express BCL-3, in addition to rare cases of small lymphocytic lymphoma/chronic lymphocytic leukemia, high-grade follicular lymphoma, and blastoid mantle cell lymphoma. The relatively high frequency of BCL-3 expression in some lymphoma types raises the possibility that BCL-3 plays an oncogenetic role in development of these neoplasms, and may be a potential target for investigational therapies.
